Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539163 | 0.82 | OPRD1 (0.40) | OPRD1CYP2D6OPRK1KCNH2SIGMAR1 | |
| SCHEMBL3537215 | 0.82 | HTT (0.37) | OPRD1CYP2D6OPRK1KCNH2OPRM1 | |
| SCHEMBL1222460 | 0.77 | OPRM1 (0.47) | CYP2D6PDK2OPRM1SLC6A2SLC6A4 | |
| SCHEMBL12991131 | 0.75 | OPRL1 (0.46) | OPRD1OPRK1KCNH2OPRM1 | |
| SCHEMBL12990832 | 0.75 | OPRL1 (0.46) | OPRD1OPRK1KCNH2OPRM1 | |
| SCHEMBL3540887 | 0.74 | PDK2 (0.46) | OPRD1OPRK1PDK2KDM4E | |
| SCHEMBL14318669 | 0.74 | PDK2 (0.30) | PDK2ALDH1A1 | |
| SCHEMBL14274099 | 0.74 | KDM4E (0.34) | PDK2SLC6A3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14318676 | 0.74 | KDM4E (0.34) | PDK2SLC6A3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12990958 | 0.73 | OPRL1 (0.47) | OPRD1OPRK1SIGMAR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-2040706-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmceuticals Incorporated (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | OPRD1 1715/4885CYP2D6 72/4885OPRK1 1169/4885 |
| US-20080033002-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | OPRD1 224/4885CYP2D6 1646/4885OPRK1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.